期刊文献+

外周血循环肿瘤细胞在卵巢癌化疗中的临床应用 被引量:6

Clinical application of peripheral blood circulating tumor cells with therapeutic effect of chemotherapy in ovarian cancer
下载PDF
导出
摘要 目的探讨卵巢癌患者外周血中循环肿瘤细胞(CTC)变化情况与化疗疗效的关系。方法选择2013年2月至2015年4月间在我院接受化疗的卵巢癌患者28例,分别抽取其化疗前后外周静脉血4 ml,采用免疫磁珠微粒阴性富集技术和免疫荧光原位杂交技术(im FISH)检测CTC数目,以CTC≥2个/3.2 ml定义为阳性。采用RECIST 1.0版标准评价化疗疗效,观察化疗前后CTC变化与疗效的关系。结果化疗前外周血CTC阳性率为60.71%(17/28),其与肿瘤分期(P=0.019)及CA125水平(P=0.022)有关;化疗后CTC阳性率为25%(7/28)。根据化疗前后CTC的变化,将患者分为阳性-阳性、阳性-阴性、阴性-阳性、阴性-阴性4组,4组有效率分别为80.0%(4/5)、83.3%(10/12)、0(0/2)和88.9%(8/9),差异有统计学意义(P=0.045)。结论化疗前后CTC变化与疗效有一定关系,CTC可作为评估卵巢癌化疗疗效的参考指标。 Objective To investigate the relationship between the change of circulating tumor cells ( CTC) in peripheral blood and the chemotherapy effect of ovarian cancer. Methods A total of 28 ovarian cancer patients treated with chemotherapy in our department from February 2013 to April 2015 were enrolled in this study. Venous blood samples of 4 ml were collected from them before and after chemotherapy. The CTC in peripheral blood were purified by negative selection using immunomagnetic, and detected by im-mune fluorescence in situ hybridization (imFISH). The CTC number over 2 in 3. 2 ml was defiend as positive. The RECIST 1. 0 criteria was used to assess the efficiency of chemotherapy, the relationship between the change of CTC before and after chemotherapy to the therapeutic effect of chemotherapy was studied. Results The positive rate of CTC before chemotherapy was 60. 71%(17/ 28), which was related with tumor stage (P= 0. 017) and CA125 levels (P= 0. 049), while it of CTC detected after chemotherapy was 25%(7/28). According to the status of CTC before and after chemotherapy,the patients were divided into 4 groups,that is,positive to positive, positive to negative, negative to positive and negative to negative groups.Their efficiencies was 80%(4/ 5),83. 33%(10/ 12),0(0/ 2) and 88. 89%(8/ 9) respectively, with significant difference(P = 0. 045). Conclusion The changes of CTC before and after chemo-therapy has a certain relationship with the efficiency to chemotherapy. CTC can be regarded as a predictor for evaluating chemotherapy.
出处 《临床肿瘤学杂志》 CAS 2016年第5期427-430,共4页 Chinese Clinical Oncology
关键词 卵巢癌 化学治疗 循环肿瘤细胞 Ovarian cancer Chemotherapy Circulating tumor cells
  • 相关文献

参考文献16

  • 1Aleffi GD, Gallenberg MM, Cliby WA, et al. Current management strategies for ovarian cancer [ J ]. Mayo Clin Proc, 2007,82(6) :751-770.
  • 2吴继海,吴效普.影像学与肿瘤标志物在卵巢癌诊断中的应用研究[J].中国医药指南,2010,8(22):82-84. 被引量:5
  • 3单伟伟,鹿欣.循环肿瘤细胞在卵巢上皮性癌中应用的研究进展[J].中华妇产科杂志,2014,49(12):948-950. 被引量:3
  • 4Paehmarm K, Clement JH, Schneider C P, et al. Standardized quantification of circulating peripheral tumor cells from lung and breast cancer[J].Clin Chem Lab Med, 2005, 3(6) :617-627.
  • 5Paterlini-Brechot P, Benali NL. Circulating tumor ceils (CTC) detection : clinical impact and future directions [ J ]. Cancer Lett, 2007,253 (2) : 180- 204.
  • 6Weigeh B, Botma AJ, Hart AA, et al.btarker genes for circulating tumor cells predict survival in metastasized breast cancer patients [J]. BJC, 2003, 88 (7) :1091-1094.
  • 7Cohen SJ, Punt CJ, lannotti N, et al.Relationship of circulating tumor cells to tumor response, progreasion-free survival, and overall survival in patients with metastatic eolorectal cancer[ J ]. J Chn Oncol,2008,26(19) :3213-3221.
  • 8Wimberger P, Heubner M, Otterbach F, et al. Influence of plati- num-based chemotherapy on disseminated tumor cells in blood and bone marrow of patients with ovarian cancer[ J]. Gynecol On- col,2007,107(2) :331-338.
  • 9Poveda A, Kaye SB, McCormack R, et al. Circulating tumor ceils predict progression free survival and overall survival in pa- tients with relapsed/recurrent advanced ovarian cancer [ J ]. Gy- necol Oncol, 2011, 122 (3) :567-572.
  • 10Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors [ J ]. JNCI, 2000, 92(3) :205-216.

二级参考文献33

  • 1朱建龙,冯令达,邵敬於,凌梅立,陆惠娟.转移性卵巢癌临床研究分析[J].中国临床医学,2005,12(3):486-488. 被引量:11
  • 2黎喜.螺旋CT诊断卵巢癌的临床价值.中国现代影像学杂志,2005,2(3):35-37.
  • 3连利娟,林巧稚.妇科肿瘤学[M].4版.北京:人民卫生出版社,2006:604.
  • 4Jenks S. Setting the bar higher for ovarian cancer survival[J]. J Natl Cancer Inst, 2014,106:4-6.
  • 5Martignetti JA, Camacho-Vanegas O, Priedigkeit N, et al. Personalized ovarian cancer disease surveillance and detection of candidate therapeutic drug target in circulating tumor DNA [J]. Neoplasia,2014,16:97-103.
  • 6Fan T, Zhao Q, Chen JJ, et al. Clinical significance of circulating tmnor cells detected by an invasion assay in peripheral blood of patients with ovarian cancer[J]. Gynecol Oncol,2009,112:185-19 I.
  • 7Poveda A, Kaye SB, McCormack R, et al. Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer[J]. Gynecol Oncol,2011,122:567-572.
  • 8Grover PK, Cummins AG, Price TJ, et al. Circulating tumour cells: the evolving concept and the inadequacy of their enrichment by EpCAM-based methodology for basic and clinical cancer research[J]. Ann Oncol,2014,25:1506-1516.
  • 9Bonnomet A, Brysse A, Tachsidis A, et al. Epithelial-to-mesenchymal transitions and circulating tumor cells[J]. J Mammary Gland Biol Neoplasia,2010,15:261-273.
  • 10Bonnomet A, Syne L, Brysse A, et al. A dynamic in vivo model of epithelial-to-mesenchymal transitions in circulating tumor cells and metastases of breast cancer[J]. Oncogene,2012,31: 3741-3753.

共引文献6

同被引文献36

引证文献6

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部